CA2136871A1 - Composition and method for inducing satiety - Google Patents
Composition and method for inducing satietyInfo
- Publication number
- CA2136871A1 CA2136871A1 CA002136871A CA2136871A CA2136871A1 CA 2136871 A1 CA2136871 A1 CA 2136871A1 CA 002136871 A CA002136871 A CA 002136871A CA 2136871 A CA2136871 A CA 2136871A CA 2136871 A1 CA2136871 A1 CA 2136871A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- satiety
- satiety agent
- agent
- polymers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/70—Fixation, conservation, or encapsulation of flavouring agents
- A23L27/72—Encapsulation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/70—Fixation, conservation, or encapsulation of flavouring agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Child & Adolescent Psychology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A composition and method for the control of appetite having food grade nutrients as the active ingredients, and a pharma-ceutically acceptable delivery agent, formulated so that the active ingredient is released predominantly in the ileum. The active in-gredient may include sugars, fatty acids, polypeptides, and amino acids; The delivery agent may be a pH sensitive coating, a cel-lulosic polymer coating or a diazotized polymer. The composition may be formulated into pellets of between 1 and 3 mm with a density of around 1Ø The composition may be administered with a liquid as a slurry, or it may be administered in a tablet form.
The composition may be used in conjunction with any weight loss or weight maintenance program.
The composition may be used in conjunction with any weight loss or weight maintenance program.
Claims (52)
1. A method for controlling appetite comprising:
controlling the intestinal absorption of a selected satiety agent, ingested by a subject.
controlling the intestinal absorption of a selected satiety agent, ingested by a subject.
2. A method according to claim 1 further comprising:
artificially retarding the intestinal absorption of a selected satiety agent, ingested by a subject.
artificially retarding the intestinal absorption of a selected satiety agent, ingested by a subject.
3. A method for controlling appetite comprising:
artificially extending the length of contact of a selected satiety agent with a subject's intestines.
artificially extending the length of contact of a selected satiety agent with a subject's intestines.
4. A method for controlling appetite comprising:
controlling a subject's intestinal absorption of a satiety agent to achieve an absorption profile that is highest in the ileum.
controlling a subject's intestinal absorption of a satiety agent to achieve an absorption profile that is highest in the ileum.
5. A method according to claim 2 further comprising:
artificially extending the length of contact of said satiety agent with the subject's intestines.
artificially extending the length of contact of said satiety agent with the subject's intestines.
6. A method according to claim 2 further comprising:
controlling the intestinal absorption of said satiety agent to achieve an absorption profile that is highest in the ileum.
controlling the intestinal absorption of said satiety agent to achieve an absorption profile that is highest in the ileum.
7. A method according to claim 3 further comprising:
controlling the intestinal absorption of said satiety agent to achieve an absorption profile that is highest in the ileum.
controlling the intestinal absorption of said satiety agent to achieve an absorption profile that is highest in the ileum.
8. A method according to claim 5 further comprising:
controlling the intestinal absorption of said satiety agent to achieve an absorption profile that is highest in the ileum.
controlling the intestinal absorption of said satiety agent to achieve an absorption profile that is highest in the ileum.
9. A method for enhancing the potency of a selected satiety agent comprising:
artificially retarding the intestinal absorption of said satiety agent.
artificially retarding the intestinal absorption of said satiety agent.
10. A composition comprising a pharmaceutically acceptable satiety agent and a pharmaceutically acceptable delivery agent, formulated for predominant release of the satiety agent in the ileum.
11. A composition according to cla?? 10 wherein the satiety agent comprises an active ingredient selected from the group consisting of food grade nutrients, derivatives of food grade nutrients, analogs of food grade nutrients, and mixtures thereof.
12. A composition according to claim 11 wherein the satiety agent comprises an active ingredient selected from the group consisting of sugars, free fatty acids, polypeptides, amino acids, derivatives thereof, analogs thereof, suitable foods that are precursors thereto, and mixtures thereof.
13. A composition according to claim 12 wherein the active ingredient is selected from the group consisting of sodium dodecanoate, sodium dodecylsulfate and mixtures thereof.
14. A composition according to claim 10 wherein the pharmaceutically acceptable delivery agent is selected from the group consisting of ion exchange resins and enteric coatings.
15. A composition according to claim 14 wherein the delivery agent is n ion exchange resin.
16. A composition according to claim 14 wherein the delivery agent is an enteric coating.
17. A composition according to claim 16 wherein the enteric coating is selected from the group consisting of pH sensitive polymers, diazotized polymers, and cellulosic polymers.
18. A composition according to claim 17 wherein the enteric coating is selected from the group consisting of pH sensitive polymers.
19. A composition according to claim 11 wherein the satiety agent comprises an active ingredient selected from the group consisting of sugars, free fatty acids, polypeptides, amino acids, derivatives thereof, analogs thereof, suitable foods that are precursors thereto, and mixtures thereof, and the delivery agent is selected from the group consisting of ion exchange resins, pH sensitive polymers, diazotized polymers, and cellulosic polymers.
20. A composition according to claim 10 wherein the satiety agent comprises an active ingredient selected from the group consisting of sodium dodecanoate, sodium dodecylsulfate, and mixtures thereof, and the delivery agent comprises an enteric coating selected from the group consisting of pH sensitive polymers.
21. A method for controlling appetite comprising:
selecting a pharmaceutically acceptable satiety agent;
selecting a pharmaceutically acceptable delivery agent which will release the satiety agent predominantly in the ileum;
formulating a dosage form; and orally administering to a subject an effective dosage.
selecting a pharmaceutically acceptable satiety agent;
selecting a pharmaceutically acceptable delivery agent which will release the satiety agent predominantly in the ileum;
formulating a dosage form; and orally administering to a subject an effective dosage.
22. A method according to claim 21 further comprising:
administering said satiety agent to the subject at such a time that maximum satiety occurs at about the next meal time.
administering said satiety agent to the subject at such a time that maximum satiety occurs at about the next meal time.
23 23. A method according to claim 21 wherein the dosage is in a tablet form.
24. A method according to claim 21 wherein the dosage is in a liquid form.
25. A method according to claim 21 wherein the dosage is in a multi-particle capsule form.
26. A method according to claim 21 wherein the dosage is in a powder form.
27. A method according to claim 21 wherein the satiety agent comprises an active ingredient selected from the group consisting of sugars, free fatty acids, polypeptides, amino acids, derivatives thereof, analogs thereof, suitable foods that are precursors thereto, and mixtures thereof, and wherein the pharmaceutically acceptable delivery agent is selected from the group consisting of enteric coatings.
28. A method according to claim 27 wherein the enteric coating is selected from the group consisting of pH sensitive polymers, diazotized polymers, and cellulosic polymers.
29. A method according to claim 28 further comprising encapsulating the selected active ingredient with the selected enteric coating into particles of between 1 and 3 millimeters in diameter.
30. A method according to claim 29 wherein the particles have a density of between 0.5 and 2Ø
31. A method according to claim 30 wherein the particles have a density of between 0.75 and 1.25.
32. A method according to claim 31 further comprising administering the particles in a multi-particle capsule form.
33. A method according to claim 31 further comprising mixing the particles with a liquid, and administering the resultant mixture to an animal.
34. An appetite control tablet comprising:
a satiety agent comprising an active ingredient selected from the group consisting of sugars, free fatty acids, polypeptides, amino acids, derivatives thereof, analogs thereof, mixtures thereof, and suitable foods that are precursors thereto, and a delivery agent selected from the group consisting of ion exchange resins, pH sensitive polymers, diazotized polymers, and cellulosic polymers.
a satiety agent comprising an active ingredient selected from the group consisting of sugars, free fatty acids, polypeptides, amino acids, derivatives thereof, analogs thereof, mixtures thereof, and suitable foods that are precursors thereto, and a delivery agent selected from the group consisting of ion exchange resins, pH sensitive polymers, diazotized polymers, and cellulosic polymers.
35. An appetite control tablet according to claim 34 wherein the satiety agent comprises an active ingredient selected from the group consisting of sodium dodecanoate, sodium dodecyl-sulfate, and mixtures thereof, and the delivery agent comprises an enteric coating selected from the group consisting of pH sensitive polymers.
36. An appetite control liquid comprising:
a satiety agent comprising an active ingredient selected from the group consisting of sugars, free fatty acids, polypeptides, amino acids, derivatives thereof, analogs thereof, mixtures thereof, and suitable foods that are precursors thereto, and a delivery agent selected from the group consisting of ion exchange resins, pH sensitive polymers, diazotized polymers, and cellulosic polymers.
a satiety agent comprising an active ingredient selected from the group consisting of sugars, free fatty acids, polypeptides, amino acids, derivatives thereof, analogs thereof, mixtures thereof, and suitable foods that are precursors thereto, and a delivery agent selected from the group consisting of ion exchange resins, pH sensitive polymers, diazotized polymers, and cellulosic polymers.
37. An appetite control liquid according to claim 36 wherein the satiety agent comprises an active ingredient selected from the group consisting of sodium dodecanoate, sodium dodecylsulfate, and mixtures thereof, and the delivery agent comprises an enteric coating selected from the group consisting of pH sensitive polymers.
38. An appetite control powder comprising:
a satiety agent comprising an active ingredient selected from the group consisting of sugars, free fatty acids, polypeptides, amino acids, derivatives thereof, analogs thereof, mixtures thereof, and suitable foods that are precursors thereto, and a delivery agent selected from the group consisting of ion exchange resins, pH sensitive polymers, diazotized polymers, and cellulosic polymers.
a satiety agent comprising an active ingredient selected from the group consisting of sugars, free fatty acids, polypeptides, amino acids, derivatives thereof, analogs thereof, mixtures thereof, and suitable foods that are precursors thereto, and a delivery agent selected from the group consisting of ion exchange resins, pH sensitive polymers, diazotized polymers, and cellulosic polymers.
39. An appetite control powder according to claim 38 wherein the satiety agent comprises an active ingredient selected from the group consisting of sodium dodecanoate, sodium dodecyl-sulfate, and mixtures thereof, and the delivery agent comprises an enteric coating selected from the group consisting of pH sensitive polymers.
40. An appetite control multi-particle capsule comprising:
a satiety agent comprising an active ingredient selected from the group consisting of sugars, free fatty acids, polypeptides, amino acids, derivatives thereof, analogs thereof, mixtures thereof, and suitable foods that are precursors thereto, and a delivery agent selected from the group consisting of ion exchange resins, pH sensitive polymers, diazotized polymers, and cellulosic polymers.
a satiety agent comprising an active ingredient selected from the group consisting of sugars, free fatty acids, polypeptides, amino acids, derivatives thereof, analogs thereof, mixtures thereof, and suitable foods that are precursors thereto, and a delivery agent selected from the group consisting of ion exchange resins, pH sensitive polymers, diazotized polymers, and cellulosic polymers.
41. An appetite control multi-particle capsule according to claim 40 wherein the satiety agent comprises an active ingredient selected from the group consisting of sodium dodecanoate, sodium dodecyl-sulfate, and mixtures thereof, and the delivery agent comprises an enteric coating selected from the group consisting of pH sensitive polymers.
42. An appetite control multiparticle capsule according to claim 41 further comprising particles which are between 1 and 3 millimeters in diameter.
43. An appetite control multiparticle capsule according to claim 42 wherein the particles have a density between 0.6 and 2Ø
44. An appetite control multiparticle capsule according to claim 43 wherein the particles have a density between 0.75 and 1.25.
45. A method for controlling appetite comprising:
regulating the availability, for intestinal absorption, of a selected satiety agent ingested by a subject.
regulating the availability, for intestinal absorption, of a selected satiety agent ingested by a subject.
46. A method according to claim 45 further comprising:
artificially delaying the availability, for intestinal absorption, of a selected satiety agent ingested by a subject.
artificially delaying the availability, for intestinal absorption, of a selected satiety agent ingested by a subject.
47. A method for controlling appetite comprising:
regulating the availability of a selected satiety agent for intestinal absorption to artificially extend the length of a subject's intestines over which the satiety agent is absorbed.
regulating the availability of a selected satiety agent for intestinal absorption to artificially extend the length of a subject's intestines over which the satiety agent is absorbed.
48. A method for controlling appetite comprising:
regulating the availability, for intestinal absorption, of a satiety agent to achieve an absorption profile that is highest in the ileum.
regulating the availability, for intestinal absorption, of a satiety agent to achieve an absorption profile that is highest in the ileum.
49. A method according to claim 46 further comprising:
artificially extending the length of contact of said satiety agent with the subject's intestines.
artificially extending the length of contact of said satiety agent with the subject's intestines.
50. A method according to claim 46 further comprising:
regulating the availability, for intestinal absorption, of said satiety agent to achieve an absorption profile that is highest in the ileum.
regulating the availability, for intestinal absorption, of said satiety agent to achieve an absorption profile that is highest in the ileum.
51. A method according to claim 47 further comprising:
regulating the availability, for intestinal absorption, of said satiety agent to achieve an absorption profile that is highest in the ileum.
regulating the availability, for intestinal absorption, of said satiety agent to achieve an absorption profile that is highest in the ileum.
52. A method according to claim 49 further comprising:
regulating the availability, for intestinal absorption, of said satiety agent to achieve an absorption profile that is highest in the ileum.
regulating the availability, for intestinal absorption, of said satiety agent to achieve an absorption profile that is highest in the ileum.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/889,710 US5322697A (en) | 1992-05-28 | 1992-05-28 | Composition and method for inducing satiety |
| US07/889,710 | 1992-05-28 | ||
| PCT/US1993/005193 WO1993024113A1 (en) | 1992-05-28 | 1993-05-28 | Composition and method for inducing satiety |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2136871A1 true CA2136871A1 (en) | 1993-12-09 |
| CA2136871C CA2136871C (en) | 2009-12-08 |
Family
ID=25395645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002136871A Expired - Lifetime CA2136871C (en) | 1992-05-28 | 1993-05-28 | Composition and method for inducing satiety |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US5322697A (en) |
| EP (1) | EP0671907A4 (en) |
| JP (1) | JPH07507546A (en) |
| AU (1) | AU684710B2 (en) |
| CA (1) | CA2136871C (en) |
| WO (1) | WO1993024113A1 (en) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
| CA2220451A1 (en) * | 1995-05-17 | 1996-11-21 | Cedars-Sinai Medical Center | Methods and compositions for improving digestion and absorption in the small intestine |
| US6558708B1 (en) | 1995-05-17 | 2003-05-06 | Cedars-Sinai Medical Center | Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
| US7048906B2 (en) * | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| US6548084B2 (en) * | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
| US6322819B1 (en) * | 1998-10-21 | 2001-11-27 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
| US6441741B1 (en) | 1999-05-17 | 2002-08-27 | Avid Identification Systems, Inc. | Overmolded transponder |
| US6387361B1 (en) * | 1999-08-02 | 2002-05-14 | Harvey Rosner | Use for drug acarbose precose for weight control prevention of weight gain for weight loss for treatment and prevention of obesity |
| ES2435094T3 (en) | 2000-05-19 | 2013-12-18 | C.R. Bard, Inc. | Device and method of tissue capture and suturing |
| US7025984B1 (en) * | 2000-06-26 | 2006-04-11 | The Procter & Gamble Company | Compositions and methods for body weight management |
| AU2001284774A1 (en) * | 2000-08-11 | 2002-02-25 | Temple University Of The Commonwealth System Of Higher Education | Obesity controlling method |
| US7737109B2 (en) * | 2000-08-11 | 2010-06-15 | Temple University Of The Commonwealth System Of Higher Education | Obesity controlling method |
| AU2002232575A1 (en) * | 2000-12-15 | 2002-06-24 | Pacifichealth Laboratories, Inc. | Nutritional composition for improving the efficacy of a lipase inhibitor |
| EP1377280B1 (en) * | 2001-04-09 | 2007-07-18 | Danisco USA, Inc. | Use of bulking agents as satiety agents |
| US6635015B2 (en) * | 2001-04-20 | 2003-10-21 | The Procter & Gamble Company | Body weight management system |
| US6929800B2 (en) | 2001-08-06 | 2005-08-16 | Abdul Rasoul Salman | Nasal passage cleaning composition |
| US20030060483A1 (en) * | 2001-09-24 | 2003-03-27 | Day Charles E. | Method of increasing pharmaceutical market |
| US8143062B2 (en) * | 2001-11-30 | 2012-03-27 | Hirsch Alan R | Method and composition for enhancing weight loss |
| FI20020078A (en) * | 2002-01-15 | 2003-07-16 | Danisco | Stimulation of the immune system by polydextrosis |
| US20030203004A1 (en) * | 2002-04-24 | 2003-10-30 | Kelm Gary Robert | Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight |
| US20060100171A1 (en) * | 2002-09-09 | 2006-05-11 | Ekhart Peter F | Branched alpha-glucans for weight management |
| US7108869B2 (en) * | 2002-11-07 | 2006-09-19 | Access Business Group International Llc | Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors |
| TWI355276B (en) * | 2003-01-14 | 2012-01-01 | Akira Tsuji | Gastrointestinal absorption enhancer mediated by p |
| BRPI0410524A (en) * | 2003-05-28 | 2006-06-20 | Unilever Nv | food product and method of preparation of a food product |
| EP1633212B1 (en) * | 2003-05-28 | 2010-01-06 | Unilever N.V. | Satiety enhancing food products |
| US20050038415A1 (en) * | 2003-08-06 | 2005-02-17 | Rohr William L. | Method and apparatus for the treatment of obesity |
| US20050032892A1 (en) * | 2003-08-07 | 2005-02-10 | The Procter & Gamble Company | Compositions, kits, and methods for treating gastrointestinal conditions |
| US7314489B2 (en) * | 2003-08-20 | 2008-01-01 | Ethicon Endo-Surgery, Inc. | Method and apparatus to facilitate nutritional malabsorption |
| US7931693B2 (en) * | 2004-02-26 | 2011-04-26 | Endosphere, Inc. | Method and apparatus for reducing obesity |
| US8147561B2 (en) | 2004-02-26 | 2012-04-03 | Endosphere, Inc. | Methods and devices to curb appetite and/or reduce food intake |
| US8585771B2 (en) | 2004-02-26 | 2013-11-19 | Endosphere, Inc. | Methods and devices to curb appetite and/or to reduce food intake |
| US7500679B2 (en) * | 2004-10-08 | 2009-03-10 | Wade James T | Board for supporting front of snow vehicle |
| WO2006068970A2 (en) * | 2004-12-21 | 2006-06-29 | Mitchell Roslin | Anastomotic outlet revision |
| US20060165756A1 (en) * | 2005-01-27 | 2006-07-27 | Catani Steven J | Method for weight management |
| US20070082085A1 (en) * | 2005-10-07 | 2007-04-12 | Catani Steven J | Compositions and methods for reducing food intake and controlling weight |
| US20070082084A1 (en) * | 2005-10-07 | 2007-04-12 | Catani Steven J | Methods for weight management |
| US20070082115A1 (en) * | 2005-10-07 | 2007-04-12 | Aimutis William Ronald Jr | Methods for inducing satiety, reducing food intake and reducing weight |
| US20070082030A1 (en) * | 2005-10-07 | 2007-04-12 | Aimutis William R | Fiber satiety compositions |
| US20070082025A1 (en) * | 2005-10-07 | 2007-04-12 | Catani Steven J | Methods for achieving and maintaining weight loss |
| US20070082028A1 (en) * | 2005-10-07 | 2007-04-12 | Aimutis William R Jr | Compositions and methods for inducing satiety and reducing caloric intake |
| US20070082108A1 (en) * | 2005-10-07 | 2007-04-12 | Aimutis William R Jr | Methods for reducing calorie intake |
| US20070082029A1 (en) * | 2005-10-07 | 2007-04-12 | Aimutis William R | Fiber satiety compositions |
| US20070082114A1 (en) * | 2005-10-07 | 2007-04-12 | Catani Steven J | Methods for reducing weight |
| US20070082026A1 (en) * | 2005-10-07 | 2007-04-12 | Aimutis William R Jr | Compositions and methods for reducing food intake and controlling weight |
| US8366650B2 (en) * | 2005-10-24 | 2013-02-05 | Satiogen Pharmaceuticals, Inc. | Biliary/pancreatic shunt device and method for treatment of metabolic and other diseases |
| US9060835B2 (en) * | 2006-05-26 | 2015-06-23 | Endosphere, Inc. | Conformationally-stabilized intraluminal device for medical applications |
| US20080085354A1 (en) * | 2006-10-06 | 2008-04-10 | Teresa Marie Paeschke | Controlled hydration of hydrocolloids |
| US20080220104A1 (en) * | 2007-03-08 | 2008-09-11 | Cappello John V | Compositions for producing satiety |
| US20110137227A1 (en) | 2007-07-16 | 2011-06-09 | Mckinley James T | Methods and devices for delivering or delaying lipids within a duodenum |
| US20090123580A1 (en) * | 2007-10-17 | 2009-05-14 | Nutracea | Methods for treating obesity, insulin resistance and inducing satiety |
| WO2010027498A2 (en) * | 2008-09-03 | 2010-03-11 | New Science Holdings, Llc | Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions |
| US9757346B2 (en) | 2008-09-03 | 2017-09-12 | Volant Holdings Gmbh | Compositions and methods for treating insulin resistance and non-insulin dependent diabetes mellitus (type II diabetes) |
| US9023408B2 (en) * | 2009-03-04 | 2015-05-05 | Meyer Nutriceuticals Llc | Composition and method for control of diabetes |
| US8282598B2 (en) | 2009-07-10 | 2012-10-09 | Metamodix, Inc. | External anchoring configurations for modular gastrointestinal prostheses |
| JP2012522595A (en) | 2009-04-03 | 2012-09-27 | メタモディクス インコーポレイテッド | Modular gastrointestinal prosthesis |
| US9278019B2 (en) | 2009-04-03 | 2016-03-08 | Metamodix, Inc | Anchors and methods for intestinal bypass sleeves |
| US8702641B2 (en) | 2009-04-03 | 2014-04-22 | Metamodix, Inc. | Gastrointestinal prostheses having partial bypass configurations |
| US9173760B2 (en) | 2009-04-03 | 2015-11-03 | Metamodix, Inc. | Delivery devices and methods for gastrointestinal implants |
| MX2011010192A (en) | 2009-04-03 | 2011-10-17 | Dms Ip Assets B V | Satiety-inducing composition. |
| US8828953B2 (en) * | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
| US9901551B2 (en) | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
| US20110106020A1 (en) * | 2009-10-29 | 2011-05-05 | Elmer Lucas B | Catheter For Deactivating At Least A Portion of the Digestive Enzymes In An Amount Of Bile |
| US20130273154A1 (en) * | 2011-03-02 | 2013-10-17 | Joseph M. Fayad | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes |
| US20140294951A1 (en) * | 2011-10-26 | 2014-10-02 | Joseph M. Fayad | Oral formulations mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and T2D |
| EP2407034A1 (en) * | 2010-07-17 | 2012-01-18 | Cognis IP Management GmbH | Particles |
| BR112013009635A2 (en) | 2010-10-19 | 2016-07-12 | Elcelyx Therapeutics Inc | chemosensory receptor ligand-based therapies |
| KR20190060879A (en) | 2011-03-02 | 2019-06-03 | 제롬 쉔타그 | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection |
| AU2014207608A1 (en) | 2013-01-15 | 2015-07-30 | Metamodix, Inc. | System and method for affecting intestinal microbial flora |
| CN115569117A (en) | 2014-08-11 | 2023-01-06 | 佩罗拉股份有限公司 | Method of inducing satiety |
| EP3679924A3 (en) | 2014-08-11 | 2020-07-29 | perora GmbH | Formulation comprising particles |
| WO2016205701A1 (en) | 2015-06-19 | 2016-12-22 | University Of Southern California | Enteral fast access tract platform system |
| CA2990230A1 (en) | 2015-06-19 | 2016-12-22 | University Of Southern California | Compositions and methods for modified nutrient delivery |
| EP3319592A1 (en) | 2015-07-07 | 2018-05-16 | perora GmbH | Method of inducing satiety |
| CA2989508A1 (en) * | 2015-07-07 | 2017-01-12 | Perora Gmbh | Formulation comprising particles and a lipase inhibitor |
| US10449075B2 (en) | 2015-12-15 | 2019-10-22 | Steven Sounyoung Yu | Biliary diversion catheter |
| BR112018016824A2 (en) * | 2016-02-18 | 2018-12-26 | Perora Gmbh | kits comprising formulations that induce satiety |
| US9622897B1 (en) | 2016-03-03 | 2017-04-18 | Metamodix, Inc. | Pyloric anchors and methods for intestinal bypass sleeves |
| KR102473258B1 (en) | 2016-05-19 | 2022-12-01 | 메타모딕스, 인코포레이티드 | Pyloric Anchor Recovery Tools and Methods |
| WO2020120519A1 (en) | 2018-12-10 | 2020-06-18 | Aphaia Pharma Ag | Combinatorial oral treatment of metabolic disorders through orchestrated release of enterokines |
| ES2906316T3 (en) | 2018-12-10 | 2022-04-18 | Aphaia Ip Ag | Pharmaceutical oral dosage forms for the treatment of metabolic disorders and related diseases through the orchestrated release of enterocins |
| IL298948A (en) | 2020-06-10 | 2023-02-01 | Aphaia Ip Ag | Pharmaceutical compositions containing enterokine-releasing substances in multiple dosage forms in combination with gelling agents |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4491578A (en) * | 1982-06-14 | 1985-01-01 | Peikin Steven R | Method of stimulating satiety in mammals |
| US4623539A (en) * | 1983-02-04 | 1986-11-18 | Tunc Deger C | Nutrient barrier polysaccharide compositions and method of use |
| SE8505569D0 (en) | 1985-11-25 | 1985-11-25 | Aco Laekemedel Ab | ENTERAL PREPARATION |
| US4857331A (en) * | 1988-03-31 | 1989-08-15 | Warner-Lambert Company | Sugarless pectin delivery system |
| FR2663818B1 (en) * | 1990-06-29 | 1993-07-09 | Rhone Poulenc Nutrition Animale | PROCESS FOR THE PREPARATION OF GRANULES OF ACTIVE PRINCIPLES BY EXTRUSION. |
| GEP19971086B (en) * | 1991-02-22 | 1997-12-02 | Tillotts Pharma Ag | Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine |
| US5273754A (en) * | 1992-03-27 | 1993-12-28 | Mann Morris A | Appetite suppressant composition and method relating thereto |
-
1992
- 1992-05-28 US US07/889,710 patent/US5322697A/en not_active Expired - Lifetime
-
1993
- 1993-05-28 JP JP6500833A patent/JPH07507546A/en not_active Ceased
- 1993-05-28 EP EP93914292A patent/EP0671907A4/en not_active Withdrawn
- 1993-05-28 AU AU44003/93A patent/AU684710B2/en not_active Expired
- 1993-05-28 WO PCT/US1993/005193 patent/WO1993024113A1/en not_active Application Discontinuation
- 1993-05-28 CA CA002136871A patent/CA2136871C/en not_active Expired - Lifetime
-
1994
- 1994-06-21 US US08263349 patent/US5753253B1/en not_active Expired - Lifetime
-
1998
- 1998-05-19 US US09/081,045 patent/US6267988B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2136871C (en) | 2009-12-08 |
| US5753253A (en) | 1998-05-19 |
| JPH07507546A (en) | 1995-08-24 |
| AU684710B2 (en) | 1998-01-08 |
| US5753253B1 (en) | 2000-11-14 |
| WO1993024113A1 (en) | 1993-12-09 |
| US6267988B1 (en) | 2001-07-31 |
| US5322697A (en) | 1994-06-21 |
| EP0671907A1 (en) | 1995-09-20 |
| EP0671907A4 (en) | 1996-09-11 |
| AU4400393A (en) | 1993-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2136871A1 (en) | Composition and method for inducing satiety | |
| KR890004686B1 (en) | Multiple-unit drug formulation | |
| CA1248023A (en) | Diffusion coated multiple-units dosage form | |
| US5382601A (en) | Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof | |
| US2738303A (en) | Sympathomimetic preparation | |
| US3184386A (en) | Prolonged action medicinal tablets | |
| US3080294A (en) | Sustained release type of pharmaceutical vehicles | |
| EP0153105A2 (en) | Diffusion coated multiple-units dosage form | |
| CA1110973A (en) | Rumen stable pellets | |
| US5275825A (en) | Compressed-molded preparations | |
| US3148124A (en) | Method of preparing sustained release pharmaceutical tablets | |
| GB2087235A (en) | A granular delayed-release form of pharmaceutical active substances | |
| IE57954B1 (en) | Storage-stable,quick disintegrating tablets | |
| CA2214788A1 (en) | Controlled dissolution pellet containing calcium sulfate | |
| AU4657085A (en) | High density, delayed release lacquered pharmaceutical pellets | |
| MXPA06001260A (en) | Calcium carbonate granulation. | |
| CA2407072A1 (en) | Taste masking coating composition | |
| HU186538B (en) | Process for producing retarde pharmaceutical compositions containing bromohexine | |
| ATE376414T1 (en) | CONTROLLED RELEASE PELLET FORMULATION | |
| JPH08506802A (en) | Corrugated drug delivery system | |
| JPH0532562A (en) | Active substance preparation for oral administration to ruminant and method for feeding nutriment or veterinary drug to ruminant | |
| IE61166B1 (en) | Pharmaceutical formulations of acrivastine | |
| BG65117B1 (en) | Spheroids, composition and method of obtaining them | |
| NO157964B (en) | PROCEDURE FOR THE MANUFACTURING OF QUICK-EXTENSIBLE PHARMACEUTICAL PRESSURES. | |
| JPS63501684A (en) | Stable pellets in rumen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |